AU000000TLX2
© PR Newswire
23.09.2024
TLX
LISTED
ASX
Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform
News Preview
MELBOURNE, Australia, INDIANAPOLIS and LAKE MARY, Fla., Sept. 23, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RLS (USA) Inc. (RLS, RLS Radiopharmacies), America's only Joint Commission-accredited radiopharmacy network distributing PET[1], SPECT[2] and therapeutic radiopharmaceuticals, today announced an a...
Themefolio
Profiler
Peergroup
© PR Newswire
23.09.2024
TLX
LISTED
ASX
Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform
News Preview
MELBOURNE, Australia, INDIANAPOLIS and LAKE MARY, Fla., Sept. 23, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RLS (USA) Inc. (RLS, RLS Radiopharmacies), America's only Joint Commission-accredited radiopharmacy network distributing PET[1], SPECT[2] and therapeutic radiopharmaceuticals, today announced an a...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2024
TLX
LISTED
ASX
Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Ind. and LAKE MARY, Fla., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RLS (USA) Inc. (RLS, RLS Radiopharmacies), America’s only Joint Commission-accredited radiopharmacy network distributing PET1, SPECT2 and therapeutic radiopharmaceuticals, today annou...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
17.09.2024
TLX
LISTED
ASX
Telix Announces Cardinal Health as U.S. Commercial Distributor for Zircaix®
News Preview
MELBOURNE, Australia, Sept. 18, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has selected Cardinal Health, Inc. (NYSE: CAH, Cardinal Health) as a commercial radiopharmaceutical distributor to supply finished unit doses of its PET[1] agent, Zircaix®[2] (TLX250-CDx) for the imaging of kid...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
17.09.2024
TLX
LISTED
ASX
Telix Announces Cardinal Health as U.S. Commercial Distributor for Zircaix®
News Preview
MELBOURNE, Australia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has selected Cardinal Health, Inc. (NYSE: CAH, Cardinal Health) as a commercial radiopharmaceutical distributor to supply finished unit doses of its PET1 agent, Zircaix®2 (TLX250-CDx) for the imaging of kid...
Themefolio
Profiler
Peergroup
© PR Newswire
11.09.2024
TLX
LISTED
ASX
'Highly Accurate': Telix's Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology
News Preview
MELBOURNE, Australia, Sept. 10, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that primary results from its Phase III ZIRCON[1] trial have been published in The Lancet Oncology, reporting that Telix's first-in-class investigational PET[2] agent, TLX250-CDx (Zircaix®[3], 89Zr-girentuximab), is hi...
Themefolio
Profiler
Peergroup
© PR Newswire
11.09.2024
TLX
LISTED
ASX
'Highly Accurate': Telix's Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology
News Preview
MELBOURNE, Australia, Sept. 11, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that primary results from its Phase III ZIRCON[1] trial have been published in The Lancet Oncology, reporting that Telix's first-in-class investigational PET[2] agent, TLX250-CDx (Zircaix®[3], 89Zr-girentuximab), is hi...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.09.2024
TLX
LISTED
ASX
‘Highly Accurate’: Telix’s Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology
News Preview
MELBOURNE, Australia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that primary results from its Phase III ZIRCON1 trial have been published in The Lancet Oncology, reporting that Telix’s first-in-class investigational PET2 agent, TLX250-CDx (Zircaix®3, 89Zr-girentuximab), is high...
Themefolio
Profiler
Peergroup
© PR Newswire
04.09.2024
TLX
LISTED
ASX
IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances
News Preview
MELBOURNE, Australia, Sept. 4, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Company's IPAX-1 Phase I study has been published in Neuro-Oncology Advances, confirming the safety and tolerability profile, and early efficacy of TLX101 therapy, in combination with external beam radiation th...
Themefolio
Profiler
Peergroup
© PR Newswire
04.09.2024
TLX
LISTED
ASX
IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances
News Preview
MELBOURNE, Australia, Sept. 4, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Company's IPAX-1 Phase I study has been published in Neuro-Oncology Advances, confirming the safety and tolerability profile, and early efficacy of TLX101 therapy, in combination with external beam radiation th...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.09.2024
TLX
LISTED
ASX
IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances
News Preview
MELBOURNE, Australia, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Company’s IPAX-1 Phase I study has been published in Neuro-Oncology Advances, confirming the safety and tolerability profile, and early efficacy of TLX101 therapy, in combination with external beam radiati...
Themefolio
Profiler
Peergroup
© PR Newswire
28.08.2024
TLX
LISTED
ASX
Telix Submits NDA for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
News Preview
MELBOURNE, Australia, Aug. 28, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-CDx, (Pixclara®[1], 18F-floretyrosine or 18F-FET), an investigational PET[2] agent for the characte...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
28.08.2024
TLX
LISTED
ASX
Telix Submits NDA for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
News Preview
MELBOURNE, Australia, Aug. 28, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-CDx, (Pixclara®[1], 18F-floretyrosine or 18F-FET), an investigational PET[2] agent for the characte...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.08.2024
TLX
LISTED
ASX
Telix Submits NDA for TLX101-CDx (Pixclara™) Brain Cancer Imaging Agent
News Preview
MELBOURNE, Australia, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-CDx, (Pixclara™1, 18F-floretyrosine or 18F-FET), an investigational PET2 agent for the characte...
Themefolio
Profiler
Peergroup
© PR Newswire
27.08.2024
TLX
LISTED
ASX
Telix Announces Reorganisation to Deliver on Strategic Priorities
News Preview
MELBOURNE, Australia, Aug. 27, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces new leadership appointments as part of an internal reorganisation to align its operations across four business units, reflecting its focus as a therapeutics-led radiopharmaceutical company committed to precision oncolog...
Themefolio
Profiler
Peergroup
© PR Newswire
27.08.2024
TLX
LISTED
ASX
Telix Announces Reorganisation to Deliver on Strategic Priorities
News Preview
MELBOURNE, Australia, Aug. 27, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces new leadership appointments as part of an internal reorganisation to align its operations across four business units, reflecting its focus as a therapeutics-led radiopharmaceutical company committed to precision oncolog...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.08.2024
TLX
LISTED
ASX
Telix Announces Reorganisation to Deliver on Strategic Priorities
News Preview
MELBOURNE, Australia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces new leadership appointments as part of an internal reorganisation to align its operations across four business units, reflecting its focus as a therapeutics-led radiopharmaceutical company committed to precision onc...
Themefolio
Profiler
Peergroup
© PR Newswire
22.08.2024
TLX
LISTED
ASX
Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities
News Preview
MELBOURNE, Australia, Aug. 22, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the half-year ended 30 June 2024. All figures are in AU$ unless otherwise stated.[1]...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.08.2024
TLX
LISTED
ASX
Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities
News Preview
MELBOURNE, Australia, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the half-year ended 30 June 2024. All figures are in AU$ unless otherwise stated.1...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.07.2024
TLX
LISTED
ASX
FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent
News Preview
MELBOURNE, Australia, July 24, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the filing of its New Drug Application (NDA) for TLX007-CDx, a new and proprietary cold kit (“Kit”) for the preparation of PSMA-PET imagi...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.07.2024
TLX
LISTED
ASX
Q2 2024 Revenue and Business Highlights, Guidance Upgrade
News Preview
MELBOURNE, Australia, July 18, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended 30 June 2024 (Q2 2024)....
Themefolio
Profiler
Peergroup
© Globe Newswire
11.07.2024
TLX
LISTED
ASX
Telix Welcomes CMS Proposal to Improve Payment for Specialised Diagnostic Radiopharmaceuticals
News Preview
MELBOURNE, Australia, July 11, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes proposed changes announced by the Centers for Medicare & Medicaid Services (CMS) for the Hospital Outpatient Prospective Payment System (OPPS) rule to improve payments for diagnostic radiopharmaceuticals1 for Med...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.06.2024
TLX
LISTED
ASX
Telix Completes TLX250-CDx (Zircaix™) BLA Submission for Kidney Cancer Imaging
News Preview
MELBOURNE, Australia, June 03, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed the submission of a Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for its investigational radiodiagnostic PET1 agent, TLX250-CDx (Zircaix™2,...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.05.2024
TLX
LISTED
ASX
Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer
News Preview
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces additional positive data from the ProstACT SELECT trial (“SELECT”) of TLX591 (177Lu rosopatamab tetraxetan), a lutetium-labelled rADC therapy for the treatment of adult patients with PSMA-positive metastatic castrate...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.05.2024
TLX
LISTED
ASX
Telix Submits NDA for New Prostate Cancer Imaging Agent
News Preview
MELBOURNE, Australia, May 28, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX007-CDx, a new and proprietary cold kit (“Kit”) for the preparation of PSMA-PET imaging1 for prostat...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.05.2024
TLX
LISTED
ASX
Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
News Preview
MELBOURNE, Australia, May 21, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the successful completion of CUPID1, a first-in-human Phase I dose escalation study of TLX592 in patients with advanced prostate cancer....
Themefolio
Profiler
Peergroup
© Globe Newswire
17.05.2024
TLX
LISTED
ASX
Telix Files Registration Statement for Proposed Initial Public Offering in the United States
News Preview
MELBOURNE, Australia, May 17, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has filed a registration statement on Form F-1 (Registration Statement) with the United States (U.S.) Securities and Exchange Commission (SEC) today (U.S. time) relating to a proposed initial public offering...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
